실적분석 2026년 8월 19일

Telix Pharmaceuticals ($TLX) 1H 2026 Earnings Analysis — Final Numbers Awaited, but Q2 Revenue Tracks at $247M

Earnings Scorecard

Revenue: Final figure undisclosed (Street consensus estimate: $312M / Q2 2026 group revenue already disclosed by the company: $247M, +21% YoY) ⏳ Awaiting release

EPS: Final figure undisclosed — actual EPS cannot be verified due to the press release not yet being issued, and consensus estimates remain thin ⏳ Awaiting release

Guidance: No new guidance issued (existing range maintained) — FY2026 revenue at the high end of $950M–$970M, revenue plus other income exceeding $1B, R&D spend of $230M–$270M

Stock reaction: After-hours -0.59% ($12.05) — as of 08:48 KST on August 20

The Positives

Q2 revenue +21%: Group revenue of $247M (Q2 2026), also +7% versus the prior quarter

Precision Medicine segment +30%: Revenue of $202M (Q2 2026), led by growth in flagship diagnostic agents

$40M Regeneron milestone payment: Non-refundable cash flows directly into 1H profit/loss

Telix Pharmaceuticals is a company that sells radiodiagnostic agents that detect prostate cancer. The company disclosed that US administration volumes rose 7% during the quarter, confirming that growth is being driven by actual usage rather than price. Management also locked in guidance pointing to the upper end of the annual revenue range.

The Negatives

Final profit/loss undisclosed: Without an earnings press release as of writing, there is no basis to judge whether the company turned a profit

Manufacturing segment revenue -6%: Telix Manufacturing Solutions revenue of $45M (Q2 2026) was the only segment to retreat

R&D spend raised: Lifted to as much as $270M for FY2026, increasing the cost burden

Growth is concentrated in the diagnostics segment, while therapeutics remain in clinical stages and are not yet generating revenue. Given the expanded R&D spend, how much the 1H loss widened is the real focal point of this earnings release.

What Management Said

Management's most recent public stance came via the July 21 quarterly revenue release, noting that the company is tracking to the high end of its annual revenue target while investing more in R&D. The market read this as confidence in growth while remaining cautious about the cost ramp.

Market Reaction and Key Forward Items

With no confirmed numbers in hand, the after-hours stock hovered near flat, unable to find direction.

Whether 1H adjusted profit/loss turned positive, or whether any loss narrowed

The September 11 PDUFA decision date for Pixclara in the US

Whether the Precision Medicine segment can sustain growth in the 30% range through 2H